The DOI matches its Crossref record.
The Role of Environmental Carcinogens, Viruses, and Genetic
Open accessAbstract
Cdk9 is a member of the Cdc2-like family of kinases. Its cyclin partners are members of the family of cyclin T (T1, T2a ad T2b) and cyclin K. The Cdk9/cyclin T complexes appear to be involved in regulating several physiological processes. Cdk9/cyclin T1 belongs to the P-TEFb complex, and is responsible for the phosphorylation of the carboxyl-terminal domain (CTD) of the RNA Polymerase II, thus promoting general elongation. Cdk9 has also been described as the kinase of the TAK complex, which is homologous to the P-TEFb complex and involved in HIV replication. Cdk9 also appears to be involved in the differentiation program of several cell types, such as muscle cells, monocytes and neurons, suggesting that it may have a function in controlling specific differentiative pathways. In addition, Cdk9 seems to have an anti-apoptotic function in monocytes, that may be related to its control over differentiation of monocytes. This data suggests the involvement of Cdk9 in several physiological processes in the cell, the deregulation of which may be related to the genesis of transforming events, that may in turn lead to the onset of cancer. In addition, since the complex Cdk9/cyclin T1 is able to bind to the HIV-1 product Tat, the study of the functions of Cdk9/cyclin T may be of interest in understanding the basal mechanisms that regulate HIV replication.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Targeting microRNAs in cancer: rationale, strategies and challenges
Garzon, R., Marcucci, G., & Croce, C. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3179 · Cited by 1,493
MicroRNAs and other non-coding RNAs as targets for anticancer drug development
Ling, H., Fabbri, M., & Calin, G. A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4140 · Cited by 1,465
Antisense oligonucleotides: the next frontier for treatment of neurological disorders
Rinaldi, C., & Wood, M. J. A. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.148 · Cited by 788
Regulation of matrix metalloproteinase gene expression
Yan, C., & Boyd, D. D. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.20948 · Cited by 754
Phosphorothioates, Essential Components of Therapeutic Oligonucleotides
Eckstein, F. (2014) · Nucleic Acid Therapeutics · doi:10.1089/nat.2014.0506 · Cited by 684
Cellular uptake and trafficking of antisense oligonucleotides
Crooke, S. T., Wang, S., Vickers, T. A., Shen, W., & Liang, X.-H. (2017) · Nature Biotechnology · doi:10.1038/nbt.3779 · Cited by 582
Approaches for the sequence-specific knockdown of mRNA
Scherer, L. J., & Rossi, J. J. (2003) · Nature Biotechnology · doi:10.1038/nbt915 · Cited by 455
The pathogenesis of mesothelioma
Carbone, M., Kratzke, R. A., & Testa, J. R. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.30227 · Cited by 392
Self-citationsiRNA-based approaches in cancer therapy
Devi, G. R. (2006) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700931 · Cited by 353
Frazier, K. S. (2015) · Toxicologic Pathology · doi:10.1177/0192623314551840 · Cited by 334
Bcl2 family proteins in carcinogenesis and the treatment of cancer
Frenzel, A., Grespi, F., Chmelewskij, W., & Villunger, A. (2009) · Apoptosis · doi:10.1007/s10495-008-0300-z · Cited by 331
Campbell, M. A., & Wengel, J. (2011) · Chemical Society Reviews · doi:10.1039/c1cs15048k · Cited by 279
Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?
Baig, S., Seevasant, I., Mohamad, J., Mukheem, A., Huri, H. Z., & Kamarul, T. (2016) · Cell Death & Disease · doi:10.1038/cddis.2015.275 · Cited by 279
Mesothelioma Epidemiology, Carcinogenesis, and Pathogenesis
Yang, H., Testa, J. R., & Carbone, M. (2008) · Current Treatment Options in Oncology · doi:10.1007/s11864-008-0067-z · Cited by 274
Self-citationLong Noncoding RNAs in Cancer and Therapeutic Potential
Renganathan, A., & Felley-Bosco, E. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-10-5203-3_7 · Cited by 260
A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes
Carbone, M., Emri, S., Dogan, A. U., Steele, I., Tuncer, M., Pass, H. I., & Baris, Y. I. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2068 · Cited by 253
Self-citationComputing in mammalian cells with nucleic acid strand exchange
Groves, B., Chen, Y.-J., Zurla, C., Pochekailov, S., Kirschman, J. L., Santangelo, P. J., & Seelig, G. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2015.278 · Cited by 220
Arbel, N., & Shoshan-Barmatz, V. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.082990 · Cited by 168
Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system
DeRosa, F., Guild, B., Karve, S., Smith, L., Love, K., Dorkin, J. R., Kauffman, K. J., Zhang, J., Yahalom, B., Anderson, D. G., et al. (2016) · Gene Therapy · doi:10.1038/gt.2016.46 · Cited by 159
Emerging Therapies in Transthyretin Amyloidosis – A New Wave of Hope After Years of Stagnancy?
Müller, M. L., Butler, J., & Heidecker, B. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1695 · Cited by 74
Injection site reactions after subcutaneous oligonucleotide therapy
van Meer, L., Moerland, M., Gallagher, J., van Doorn, M. B. A., Prens, E. P., Cohen, A. F., Rissmann, R., & Burggraaf, J. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12961 · Cited by 45
Inhibition of miR-21 in glioma cells using catalytic nucleic acids
Belter, A., Rolle, K., Piwecka, M., Fedoruk-Wyszomirska, A., Naskręt-Barciszewska, M. Z., & Barciszewski, J. (2016) · Scientific Reports · doi:10.1038/srep24516 · Cited by 36
Role of asbestos in etiology of malignant pleural mesothelioma
Godleski, J. J. (2004) · Thoracic Surgery Clinics · doi:10.1016/s1547-4127(04)00111-2 · Cited by 24
Metadata
- Authors
- Powers, A., & Carbone, M.
- Venue
- Cancer Biology & Therapy
- Publisher
- Informa UK Limited
- Published
- 2002-07-09
- Volume
- 1
- Issue
- 4
- Pages
- 347-352
- ISSN
- 1538-4047 (ISSN-L)
- 1555-8576
- OpenAlex
- W1980816809
- Cited by
- 274
- References
- 0
- FWCI
- 2.74
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.